αIIbβ3 (GPIIb-IIIa) antagonists

Dhruv Mahtta, Anthony A. Bavry

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Platelets play a key role in thrombosis and hemostasis, especially during an acute coronary syndrome and in patients undergoing percutaneous coronary intervention. Associated adverse cardiovascular events from normal platelet function can be mitigated via adequate platelet inhibition. Glycoprotein IIb-IIIa (αIIbβ3) antagonists were first introduced to the market with the intent of being potent, intravenous, antiplatelet agents with a quick onset of action. These agents have been the centerpiece of multiple well conducted investigations over the last several decades. In this chapter, we briefly discuss the pharmacological mechanism and subtle differences between the three currently available intravenous glycoprotein IIb-IIIa antagonists: abciximab, eptifibatide, and tirofiban. Furthermore, we present data from landmark clinical trials highlighting the efficacy and safety of these agents in various clinical scenarios. Lastly, we present a comparison between these agents and other antiplatelet drugs as well as the role of these agents in our modern-day clinical practice.

Original languageEnglish (US)
Title of host publicationPlatelets
PublisherElsevier
Pages957-991
Number of pages35
ISBN (Electronic)9780128134566
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Keywords

  • Abciximab
  • Cangrelor
  • Eptifibatide
  • Facilitated percutaneous coronary intervention
  • Glycoprotein IIb-IIIa
  • Primary percutaneous coronary intervention
  • Thienopyridine
  • Tirofiban
  • Upstream

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint Dive into the research topics of 'αIIbβ3 (GPIIb-IIIa) antagonists'. Together they form a unique fingerprint.

  • Cite this